Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/3/2009

CAMBRIDGE, Mass., Sept. 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the upcoming Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9, 2009 at 10:55 a.m. ET at the Four Seasons Hotel in Boston, Massachusetts, and at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September( )14, 2009 at 3:55 p.m. ET at the Grand Hyatt Hotel, New York.

The live and archived webcasts of the presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before the events to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conferences.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.

    Idenix Pharmaceuticals' Contacts:
    Media: Teri Dahlman (617) 995-9905
    Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
2. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
3. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
4. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
7. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
8. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
10. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
11. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Benchworks ... 22 in Philadelphia. The event was offered by the Chamber of Commerce for ... featured breakout groups and interaction with speakers who are leaders in their industries. ...
(Date:3/28/2017)... 28, 2017 Volition America, Inc., a wholly-owned U.S. ... engagement of Deborah Vollmer Dahlke , DrPH, CEO and ... Vollmer Dahlke,s role will be to assist the ... State of Texas and elsewhere in ... has significant experience over the past six years, helping ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... initial release of LabKey’s newest software solution, LabKey Biologics . Built in ... pharma and biotech organizations, LabKey Biologics provides drug research teams tools for biological ...
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, ... new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen ... we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and ...
Breaking Biology Technology:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
Breaking Biology News(10 mins):